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1 Introduction
Continuous fetal heart rate (FHR) monitoring
coupled with intermittent microsampling of fetal
capillary blood for acid-base status is one of the
objective methods for the evaluation of the effects
of a pharmacologic agent on the fetus. Prior to the
availability of these techniques, neonatal outcome
was the only parameter available to test the effect
of a pharmacologic agent on the fetus in clinical
practice. FHR variability as seen in a FHR tracing
is a clinical indicator of the fetal neurocardiovas-
cular integration [11]. Various drugs have been
demonstrated to alter FHR variability [4, 12, 13,
16].
A close approximation of human fetal oxygena-
tion can be measured continuously with the use
of a transcutaneous osygen electrode during the
active phase of labor [8]. Although HUGH et al.
[7] have reported a decline in human maternal
tcPoi following the administration of 50 or 100
mg meperidine intramuscularly, fetal tcPoi was
not measured. L FGREN reported that FHR varia-
bility lags behind transcutaneous Ρθ2 (tcPo2)
changes by some time [10]. The purpose of this
study is to evaluate the relationship of fetal oxyg-
enation to FHR variability and uterine activity
following the maternal administration of 50 mg
intravenous meperidine and to describe the tem-
poral relationship of alterations in FHR variabil-
ity to changes in fetal tcPo2 and uterine activity
in the human.
2 Patients and procedures
Ten patients from the Sloane Hospital for Women
at the Columbia-Presbyterian Medical Center in
New York underwent tcPo2 evaluation of fetal
oxygenation, fetal heart rate variability and uter-
ine activity. All patients in this study were in the
active phase of uncomplicated labor, maintaining
one position with cervical dilatation between three
and eight centimeters at the onset of the study.
The demographic characteristics of these patients
are given in table I. No patient received any medi-
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cation, with the exception of oxytocin which when
used was infused at a constant rate throughout
the evaluation period. The dosage and timing of
meperidine administration was determined by the
managing obstetrician using standard clinical indi-
cators. Patients were monitored using an FHR
electrode and an intrauterine catheter. Uterine
activity was measured by an open ended transcerv-
ical intrauterine catheter connected by a strain
gauge placed at the level of the patient's sternum
and quantitated either with Montevideo units or
by measuring the area under the uterine pressure
curve (uterine activity units) with an on-line tech-
nique utilizing a voltage control oscillator [6].
Fetal oxygenation was measured continuously by
a transcutaneous Ρθ2 (tcPoi) electrode in ten
patients in the manner described by HUGH [8].
The tcPoa measurements are based on the polaro-
graphic technique by which the skin is warmed to
43 °C and a deflection in the current between
platinum cathode and silver anode, caused by
molecular oxygen diffusing from the fetal epid-
ermis, is recorded as tcPoi (Oxymonitor, Litton
Co., Chicago). These electrodes are in an electro-
lyte solution and covered by a teflon membrane
which is permeable to oxygen and in contact with
the tissue from which tcPo2 is to be measured [3,
5]. The validity of this technique in this laboratory
has been established by comparing tcPo2 values
with fetal scalp capillary Ρθ2 and umbilical arterial
and venous Ρθ2 values [1].
Following shaving of the fetal scalp, the tcPo2
electrode was applied to the presenting part with
an histoacrylic glue. The tcPo2 electrode was ap-
propriately calibrated prior to uSe, and at the
termination of the observation period, tcPo2 was
correlated with either the capillary Ρθ2 value or
with Ρθ2 from umbilical arterial or venous blood
whenever possible. After stabilization of tcPo2 re-
adings, a control or preinjection measurement and
recording were obtained. Meperidine was then
administered intravenously over a two-minute
interval.
From the ten patients in New York, the interval
from the injection to the onset of decline and the
maximum decline in tcPo2 levels were recorded.
The duration of the maximum decline in tcPo2
and the interval for a return to a recovery baseline
were also observed. Visually evaluated changes in
FHR variability and uterine activity (Montevideo
units) were marked and temporal means were
obtained. Due to technical problems, computer
derived indices of FHR variability and uterine
activity could not be accomplished in New York.
At the same time, one of the investigators was
carrying out almost identical studies at the Los
Angeles County-University of Southern Califor-
nia Medical Center. Fetal heart rate and uterine
activity data from twenty patients identically man-
aged (by the same protocol) and demographically
matched at the Los Angeles County-University of
Southern California Medical Center were evalu-
ated as follows. The comparison of the two groups
of patients is given in table I. FHR variability was
computed from the "R-R" intervals obtained from
the fetal ECG signals which had been recorded at
a speed of 1 — 7/8 inches per second onto analog
magnetic tape using a high fidelity tape recorder
(Ampex PR 500 or Ampex 1260). The beat-to-
beat interval indices were calculated according to
the method of YEH, FORSYTHE and HON [15] using
a PDP-8/1 or PDP-11 computer (Digital Equip-
ment Corporation).
The differential index (DI) or short-term variabil-
ity (the standard deviation of the sequential "R-
R" interval differences) and the interval index
(II) or long-term variability (the coefficient of
variation of the standard deviation of the "R-R"
intervals) in sequential fifteen second windows
within each five minute segment were averaged
and expressed as the mean DI and II for that five-
minute segment of baseline FHR. The five-minute
averaging process was repeated every five minutes
for a one-half hour pre-injection period and for
the duration of the measured post-injection pe-
riod. Finally the mean value of each index for
each of the five-minute time segments was then
calculated for the group of twenty patients.
Uterine activity (torr minutes, uterine activity
units) was summed for each ten-minute interval of
the preinjection and postinjection period. Linear
regression analyses of the pre- and postinjection
data for uterine activity was utilized to compare
the differences of slopes between expected uterine
activity and the actual observed uterine activity.
3 Results
Fetal oxygenation measurements (tcPo2) from the
ten New York patients who received 50 mg intra-
venous meperidine are presented in table II. In
these patients the mean preinjection baseline tcPo2
was 18.6 torr. A decline in tcPo2 was noted at
3.13 minutes following the injection. The mean
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maximum decline value in tcPo2 (11.7 torr) which
lasted for an average of 4.5 minutes, was noted
9 minutes after the injection. This decline was
statistically significant (t test, P < 0.01). The
mean recovery baseline tcPo2 of 15.0 torr was
reached after an average of 15.29 minutes, ± 7.68
from the onset of the injection. There was a direct
correlation between injection to onset of decline
interval and the duration of maximum decline
(r = 0.75); as well as between duration of max-
imum decline and baseline recovery (r = 0.85).
The visually evaluated FHR variability data (from
New York) was compared to the computer derived
data (from the California patients) and were
found to correlate almost identically. A similar
correlation was found for uterine activity data
measured in Montevideo units and uterine activity
units.
The mean fifteen second window representing the
first five minute segment of baseline long- and
short-term variability following the injection of
meperidine was noted to rise slightly, and the
second five-minute interval began to decrease
which continued for each five-minute interval un-
til a maximum depth was reached at 25 minutes
with a return toward normal values by 30 minutes
postinjection.
The decline in tcPo2 and a transient increase in
FHR variablity (followed immediately by decrease
in the indices of FHR variability), after the injec-
tion of meperidine is associated with a decrease in
uterine activity which is different from the normal
positive slope curve of unmedicated uterine activ-
ity. This shift in uterine activity is significant
(P < 0.05, paired "t" test). The temporal relation-
ship of fetal tcPoz, baseline long and short term
variability (quantitated computer derived indices)
and uterine activity following the injection of 50
mg of intravenous meperidine are given in
figure 1.
The tcPo2 values, FHR variability indices, and
uterine activity changes in one patient receiving
75 mg of intravenous meperidine were similar to
those obtained in patients receiving 50 mg meper-
idine; however, no changes in tcPo2 were noted
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Figure 1. Fetal tcPo2, FHR variability (short term —DI,
long term—II) and uterine activity (uterine activity
units) ± S. E. following a two-minute injection of 50
mg meperidine at time 0 minutes.
4 Discussion
These data indicate that there is a decline in fetal
tcPo2 values shortly following intravenous injec-
tion of 50 mg meperidine. The lowest level of
oxygenation is noted approximately seven minutes
following the beginning of the injection. The dura-
tion of maximum decline lasts for approximately
five minutes, and the tcPo2 shortly returns to a
recovery baseline at a slightly lower level than the
preinjection oxygenation value. Analysis of FHR
variability indicates that there is a decrease in
short and long term indices of FHR variability
which is noted at the 10 minute postinjection
interval following a short increase in indices at 5
minutes between five and ten minutes following
the injection. This decline lasts for approximately
15 minutes with an initiation of return toward
normal baseline levels at 30 minutes postinjection.
Uterine activity is noticed to decrease almost im-
mediately following the intravenous injection of
50 mg of meperidine. This suggests that changes
in fetal tcPo2 values precede those in FHR varia-
bility. Although a decrease in maternal oxygena-
tion following meperidine injection has been re-
ported by HUGH et al. [7], the correlation between
FHR variability, fetal tcPo2 changes and uterine
activity have not been reported.
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The mechanism for the transient fall in fetal oxyg-
enation is not well understood. Inasmuch as ab-
normal umbilical cord positioning and FHR vari-
able decelerations were noted in a number of
patients, some meperidine induced exaggeration
in the reflex mediated release of acetyl choline at
the fetal sino-atrial node may be considered as a
potential mechanism. Constriction of the uterine
vasculature or fetal peripheral vasoconstriction
due either to the drug or fetal hypotension can
also represent possible etiologies. HUGH et al. [7]
demonstrated that there is a relationship between
the administration of meperidine and a decrease
in maternal respiratory effort. Perhaps this may
be a possible contributor to a decline in fetal
tcPoa, when observed; maternal emesis can be an
additonal factor.
The slight increase in indices of FHR variability
at five minutes postinjection probably represents
an alteration in the Po2/Pco2 relationship. This
change most probably is mediated by the baroche-
moreceptors. This pattern of shift in FHR varia-
bility with fetal hypoxia was first described by
STANGE et al. [14] and later supported by other
investigators including MILLER et al. [12].
No additionally significant FHR changes other
than in indices of FHR variability were noted in
these patients nor were there any shifts of perina-
tal morbidity secondary to this transient change
in oxygenation. In contrast to a longer temporal
interval of transient decrease in fetal tcPo2 levels
which are seen with paracervical block [2], the
transient decrease in tcPo2 following meperidine
injection was not felt to have clinical significance;
nevertheless, in management of fetuses with bor-
derline oxygenation, this observation should be
considered, particularly when other procedures
and techniques are utilized in which synergy could
lead to clinically overt fetal hypoxic problems.
A significant decline in fetal tcPo2 seen in some
patients may be due to peripheral vasoconstriction
resulting from elevated fetal catecholamines or for
technical reasons due to caput and moulding of
fetal head and/or compression of electrode in ad-
vanced labor [9].
The use of quantitated FHR variability from a
second but demographically matched and ident-
ically managed group of patients was of major
assistance to demonstrate quantitation of FHR
data only. The changes in FHR variability data
had already been appreciated visually, the quanti-
tated data were used to enhance the demonstra-
tion of the tcPo2-FHR variability relationship.
The analysis of uterine activity data by both
methods demonstrated a diminution following the
intravenous injection of 50 mg of meperidine.
This indicates that the transient decrease in fetal
oxygenation following meperidine injection is
probably not due to decreased intervillous space
blood flow secondary to increased uterine activity,
although this possibility cannot be totally elimin-
ated since approximately 10 percent of the patients
have been observed to have an increase of uterine
activity following the injection of this dose of
meperidine.
For completeness, intravenous doses of 25 mg and
75 mg of meperidine has been evaluated using this
protocol in a few patients. Meperidine 25 mg
administered intravenously causes no change in
tcPo2 readings and only very minimal changes in
FHR variability and uterine activity. Changes
very similar to, but somewhat more pronounced,
than those described for 50 mg intravenous meper-
idine wer recorded when meperidine 75 mg was
administered intravenously.
Summary
Fetal tcPoz levels were measured in 10 patients following
maternal administration of 50 mg of meperidine by
intravenous route. About 3 minutes following injection
of meperidine, tcPo2 values started to decline to reach
the lowest value of 37 ± 25% by 7 mins of injection.
tcPoz values recovered by about 15 mins following injec-
tion. These changes in fetal tcPo2 levels preceded trans-
ient minimal increase in FHR variability. The increase
in FHR variability was followed immediately by a de-
crease in the indices of the FHR variability. The uterine
activity began to decline below the predicted positive
slope values shortly following injection of meperidine.
This decline was maximum 15 mins post-injection, sub-
sequently establishing a trajectory toward the positive
values expected for unmedicated labor.
Two patients receiving 25 mg intravenous meperidine
demonstrated no decline in tcPo2 levels; however, in the
patient receiving 75 mg of intravenous meperidine, the
changes noted were similar to those observed following
50 mg of meperidine.
Keywords: Fetal oxygenation, fetal heart rate variability, meperidine, tcPo2, uterine activity.
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Zusammenfassung
Fetale Oxygenierung (tcPo?), Herzfrequenzvariabilitat
und uterine Aktivität nach Gabe von Dolantin® an die
Mutter
Dolantin® ist das am häufigsten eingesetzte Analgeti-
kum unter der Geburt. Um die Auswirkungen einer
intravenösen Dolantingabe auf die fetale Oxygenierung
zu erfassen, wurde bei zehn Patienten mit geringen Risi-
kofaktoren in der aktiven Geburtsphase eine kontinuier-
liche transkutane Sauerstoffpartialdruckmessung (tcPo2)
durchgeführt. Bei der Auswertung zeigte sich, daß es zu
einem vorübergehenden Abfall der tcPo2-Spiegel kommt,
der kurz nach der intravenösen Dolanthingabe einsetzt.
Etwa 15 Minuten nach der Injektion stellt sich ein neuer
Spiegel ein, der nur geringfügig niedriger als der vor der
Injektion ist. Darüber hinaus weisen die Ergebnisse auf
einen möglichen Zusammenhang zwischen dem Abfall
des tcPo2-Spiegels und der Herzfrequenzvariabilität
(FHR) und uterinen Aktivität hin. Um diesen Zusam-
menhang genauer zu überprüfen, wurden weitere 20
Patienten überwacht, die nach demografischen Kriterien
den ersten 10 Patienten mit tcPo2-Monitoring zugeord-
net wurden. Bei diesen zusätzlichen 20 Patienten war,
durch Protokolle nachgewiesen, das geburtshilfliche Ma-
nagement identisch, jedoch wurde ein Standard-Monito-
ring durchgeführt, wobei sowohl die quantitative Herz-
frequenzvariabilität mit Lang- und Kurzzeitindizes ange-
geben wurde wie auch die uterine Aktivität, wobei die
Fläche unter der Aktivitätskurve mit einem Oszillator
gemessen wurde.
Der mittlere tcPo2-Spiegel vor Injektion lag bei 18.6
torr. Das Zeitintervall von der Dolantingabe bis zum
initialen Abfall betrug 3.13 ± 1.75 Minuten und bis zum
Maximum des Abfalls 9.0 + 3.55 Minuten. Die Dauer
des Abfalls betrug 4.61 + 3.83 Minuten, der niedrigste
tcPo2-Spiegel 11.7 + 5.31 torr. Zwischen der Dolantin-
injektion und dem Einstellen einer neuen Basislinie lag
ein Zeitintervall von 15.29 ± 7.41 Minuten und ein
mittlerer tcPo2-Abfall von 47.4 ± 25.8%. Nach der In-
jektion lag der tcPo2-Wert bei 15 torr. Nach der tcPo2-
Messung wurde ein pH-Wert aus dem fetalen Scalp
bestimmt, der mit den venösen und arteriellen Blutgas-
werten in der Nabelschnur bei Geburt verglichen wurde.
Im allgemeinen gab es eine gute Übereinstimmung zwi-
schen dem letzten Scalp-pH und den umbilikalen Blut-
gajswerten. Bei Änderung des fetalen tcPo2-Spiegels kam
es zu minimalen kurzfristigen Zunahmen der FHR-Va-
riabilität. Danach fielen die Indizes ab, und mit Restabi-
lisierung der tcPo2-Werte wurden schließlich die Werte
der neuen, nur geringfügig niederigeren Basislinie nach
Injektion wieder erreicht. Dolantin® induziert Verände-
rungen des tcPo2 und der FHR-Variabilität, welche eng
miteinander gekoppelt sind.
Kurz nach der intravenösen Gabe von 50 mg Dolantin®
sinkt die uterine Aktivität unterhalb der Werte, die man
für Geburten ohne Medikation voraussagt und berech-
net hat. 15 Minuten nach Injektion ist dies am deutlich-
sten, danach werden Werte wie in der Kontrollgruppe
erreicht.
Nicht untersucht wurden die Mechanismen, die zu dem
Abfall des tcPo2 sowie den Veränderungen der FHR und
uterinen Aktivität führen. Wir vermuten, daß Dolantin®
eine Konstriktion der glatten uterinen Gefaßmuskulatur
verursacht. Es muß festgehalten werden, daß nach Gabe
von 50 mg Dolantin® keine klinisch bedeutsamen FHR-
und tcPo2-Veränderungen auftreten. Einigen wenigen
Patienten wurden 25 bzw. 75 mg Dolantin® verabreicht;
dann wurde bei ihnen das gleiche Monitoring durchge-
führt. Bei 25 mg fielen die tcPo2-Spiegel nicht ab; bei 75
mg waren die gleichen Veränderungen wie nach 50 mg
zu beobachten, jedoch ausgeprägter.
Schlüsselwörter: Dolantin®, fetale Oxygenierung, FHR-Variabilität, tcPo2, uterine Aktivität.
Resume
Oxygenation du fotus humain (tcPo2>, instabilite du
rythme cardiaque et activite uterine apres administration
maternelle de meperidine
La meperidine est Panalgesique narcotique le plus usuel-
lement utilise au cours de la phase active du travail.
Afin de determiner 1'effet de la meperidine intra-veineuse
surPoxygenation foetale, dix patiehtes ä faible rique ont
subi une surveillance continue par voie transcutanee de
la pression partielle d'oxygene (tcPo2) pendant la phase
active du travail. L'analyse de ces donnees indique qu'il
y a une diminution transitoire des taux de tcPo2 qui
commence peu de temps apres Pinjection intraveineuse
de meperidine et qui atteint le niveau de base post-
injection, niveau de base qui est legerement inferieur aux
taux de tcPo2 avant I'injection, environ 15 minutes apres
Pinjection. D'autres analyses de ces donnees indiquent
qu'il existe une relation potentielle entre la diminution
des taux de tcPo2 et Pinstabilite du rythme cardiaque
foetal (RCF) et Pactivite uterine. Dans le but d'examiner
cette relation potentielle, on a utilise un protocole identi-
que chez vingt patiente supplementaires apariees aux
dix patientes d'origine qui avaient eu une surveillance
continue de la tcPo2. Ces patientes supplementaires pri-
ses en charge de fagon identique (dans le protocole) ont
subi une surveillance standard continue avec calcul de
Pinstabilite quantitative du rythme cardiaque foetal avec
des indices du court terme et du lont terme ainsi que de
Pevaluation de Pactivite uterine avec mesure de Paire
totale de la courbe de Pactivite uterine en utilisant un
oscillateur.
La moyenne des taux de tcPo2 en pre-injection etait de
18,6 torr, et Pintervalle entre Pinjection de meperidine
et le debut de la chute initiale etait de 3,13 ± 1,75
minutes. L'intervalle entre Pinjection de meperidine et le
J. Perinat. Med. 16 (1988)
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point de la baisse maximale etait de 9,0 ± 3,55 minutes.
La duree de la pente maximale a etc de 4,61 + 3,83
minutes et la valeur la plus hasse de tcPoi a ete de 11,7
± 5,31 torr. Entre Finjection de meperidine et le retour
au niveau de base post-injection, il y a eu un Intervalle
de 15,29 + 7,41 minutes avec une diminution en pourcen-
tage de la tcPo2 de 37,4 ± 25,8%. La valeur du niveau
de base post-injection etait de 15,0 torr. Apres mesure
de la tcPo2, on a realise la mesure du pH capillaire au
scalp foetal que Γόη a compare ensuite aux valeurs des
gaz sanguins respiratoires veineux et arteriels apres la
naissance.
II y a une bonne concordance generate entre le pH
capillaire final au scalp foetal et les dosages des gaz du
sang ombilical. Les modifications de la tcPo2 foetale
precedent une augmentation transitoire minime de l'ins-
tabilite du R. C. F. Cette augmentation des parametres
de rinstabilite du R. C. F. est suivie immediatement par
une chute des indices d'instabilite du R.C.F. qui retour-
nent aux valeurs du niveau de base de la meme facon
que la tcPo2 retourne au niveau de base apres la legere
baisserpost-injection. La meperidine induit des modifica-
tions de la tcPo2 et de l'instabilite du R.C.F. qui sont
etroitement liees avec des modifications de la tcPo2 qui
precedent tout juste les alterations de Finstabilite du
R.C.F.
Peu de temps apres l'injection intra-veineuse de 50 mg de
meperidine les valeurs de Factivite uterine commencent
diminuer en dessous des valeurs positives prevues qui
avaient ete claculees partir du travail sans traitement.
On en deduit qu'une injection de meperidine peut en-
trainer une vaso-constriction transitoire au niveau des
muscles lisses vasculaires uterins. II faut noter qu' la
suite d'une injection intra-veineuse de 50 mg de meperi-
dine, il n'a pas ete observe ni de modification clinique-
ment significative du rythme cardiaque foetal, ni des taux
de tcPo2. A titre de comparaison, quelques patientes ont
re$u soit 25 mg soit 75 mt de meperidine en intra-
veineux avec enregistrement de la tcPo2 en pre et en post-
injection, surveillance de Finstabilite du R.C.F. et de
Factivite uterine.
Les deux patientes ayant re$u 25 mg de meperidine intra-
veineuse n'ont pas eu de diminution des taux de la tcPo2;
toutefois, la patiente ayant regu 75 mg a presente des
modifications similaires mais plus accentucees que celles
des patientes ayant re$u 50 mg de meperidine.
Mots-cles: Contraction uterine, instabilite du rythme cardiaque foetal, meperidine, oxygenation foetale, tcPo2.
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